Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.

MLA

Cazzaniga, Marina Elena, et al. “Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.” Breast Care (Basel, Switzerland), vol. 15, no. 1, Feb. 2020, pp. 30–37. EBSCOhost, https://doi.org/10.1159/000495469.

APA

Cazzaniga, M. E., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Valerio, M. R., Airoldi, M., Moretti, G., Ficorella, C., Gianni, L., Michelotti, A., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., … Mustacchi, G. (2020). Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. Breast Care (Basel, Switzerland), 15(1), 30–37. https://doi.org/10.1159/000495469

Chicago

Cazzaniga, Marina Elena, Claudio Verusio, Mariangela Ciccarese, Alberto Fumagalli, Donata Sartori, Maria Rosaria Valerio, Mario Airoldi, et al. 2020. “Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.” Breast Care (Basel, Switzerland) 15 (1): 30–37. doi:10.1159/000495469.